OPEN ACCESS Freely available online

Immunotherapy: Open Access

Short Comunication

The Mechanisms, Advancements and Factors of Ovarian Cancer Immunotherapy

Juan Francisco*

Department of Medicine, University of Azerbaijan, Ceyhun Hacibayli, Baki, Azerbaijan

DESCRIPTION

Ovarian cancer remains one of the most lethal gynecological cancers, characterized by late-stage diagnosis and high recurrence rates. Traditional treatments, such as surgery and chemotherapy, offer limited success in improving long-term survival rates. However, the advent of immunotherapy has been leveraging the body's immune system to target and eradicate cancer cells. The study explains into the mechanisms, current advancements, challenges and future directions of immunotherapy in the context of ovarian cancer.

Understanding immunotherapy

Immunotherapy is a type of cancer treatment that harms the power of the immune system to fight cancer. The immune system, which typically protects the body from infections and diseases, is sometimes unable to recognize cancer cells as a threat. Immunotherapy aims to stimulate or restore the immune system's ability to detect and destroy these malignant cells.

There are several types of immunotherapies, including immune checkpoint inhibitors, adoptive cell transfer, monoclonal antibodies and cancer vaccines. Each approach works differently to boost the immune response against cancer cells.

Immune checkpoint inhibitors

Immune checkpoints are regulatory pathways in the immune system that prevent autoimmunity by inhibiting overactivation of immune cells. Cancer cells often exploit these checkpoints to avoid being attacked by the immune system. Immune checkpoint inhibitors are drugs that block these checkpoint proteins, thereby enabling a stronger immune attack on cancer cells [1].

For ovarian cancer, the most notable immune checkpoint inhibitors target Programmed Death-1 (PD-1) and Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4). Drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) have shown assurance in clinical trials. However, the response rates in ovarian cancer patients have been relatively modest compared to other cancers, necessitating further research to enhance efficacy [2].

Adoptive cell transfer

Adoptive Cell Transfer (ACT) involves extracting and engineering a patient's own immune cells to better recognize and kill cancer cells and then infusing these enhanced cells back into the patient. One form of ACT, Chimeric Antigen Receptor T-Cell Therapy (CAR-T), has shown remarkable success in hematologic cancers and is being explored for ovarian cancer [3].

Many studies are investigating ways to modify T-cells to target ovarian cancer-specific antigens, such as mesothelin. Early-phase clinical trials have demonstrated the potential of this approach, but challenges remain in managing toxicities and ensuring the persistence of engineered T-cells [4].

Monoclonal antibodies

Monoclonal antibodies are lab-created molecules that can bind to specific targets on cancer cells. These antibodies can either directly kill cancer cells or mark them for destruction by the immune system. Bevacizumab (Avastin), an anti-Vascular Endothelial Growth Factor- (VEGF) antibody, is already used in ovarian cancer treatment to inhibit tumor blood vessel growth [5].

Another assuring monoclonal antibody is farletuzumab, which targets the folate receptor alpha, a protein overexpressed in many ovarian cancers. Combining monoclonal antibodies with other forms of immunotherapy or chemotherapy is a key area of ongoing studies [6].

Cancer vaccines

Cancer vaccines aim to elicit a strong immune response against specific tumor antigens. In ovarian cancer, vaccines targeting antigens like CA-125 and NY-ESO-1 are under investigation. While these vaccines have shown the ability to induce immune responses, translating these responses into clinical benefit has been challenging. Personalized cancer vaccines, made to the unique mutations present in an individual's tumor, represent a cutting-edge strategy that is currently being explored [7].

Correspondence to: Juan Francisco, Department of Medicine, University of Azerbaijan, Ceyhun Hacibayli, Baki, Azerbaijan, Email: francisco_a@jedu.com

Received: 27-May-2024, Manuscript No. IMT-24-31531; **Editor assigned:** 31-May-2024, PreQC No. IMT-24-31531 (PQ); **Reviewed:** 14-Jun-2024, QC No. IMT-24-31531; **Revised:** 21-Jun-2024, Manuscript No. IMT-24-31531 (R); **Published:** 28-Jun-2024, DOI: 10.35248/2471-9552.24.10.254

Citation: Francisco J (2024) The Mechanisms, Advancements and Factors of Ovarian Cancer Immunotherapy. Immunotherapy (Los Angel). 10:254

Challenges and future directions

Despite the potential of immunotherapy, several challenges hinder its effectiveness in ovarian cancer. The tumor microenvironment in ovarian cancer is immunosuppressive, with high levels of regulatory T-cells and myeloid-derived suppressor cells that inhibit the immune response. Overcoming this immunosuppressive milieu is crucial for the success of immunotherapy [8].

Furthermore, identifying reliable biomarkers to predict which patients will benefit from immunotherapy remains a significant hurdle. Research is ongoing to discover such biomarkers and to develop combination therapies that might enhance the efficacy of immunotherapy [9].

Looking ahead, the integration of immunotherapy with other treatment modalities, such as chemotherapy, targeted therapy and radiotherapy, holds assurance. Combination approaches may help to overcome resistance mechanisms and improve patient outcomes [10].

CONCLUSION

Immunotherapy represents a transformative approach in the battle against ovarian cancer. While significant progress has been made, ongoing studies are essential to address the challenges and fully realize the potential of immunotherapy. By continuing to resolve the complexities of the immune system and its interaction with cancer, scientists and clinicians hope to develop more effective treatments that offer lasting remissions and improved survival rates for patients with ovarian cancer.

REFERENCES

1. Guo H, Wei J, Zhang Y, Wang L, Wan J, Wang W, et al. Protein ubiquitination in ovarian cancer immunotherapy: The progress and therapeutic strategy. Gen Dis. 2023:101158.
2. Zhao Z, Xiang Y, Koellhoffer EC, Shukla S, Fiering S, Chen S, et al. 3D bioprinting cowpea mosaic virus as an immunotherapy depot for ovarian cancer prevention in a preclinical mouse model. Mater Adv. 2024;5(4):1480-1486.
3. Lin Y, Wang X, He S, Duan Z, Zhang Y, Sun X, et al. Immunostimulatory gene therapy combined with checkpoint blockade reshapes tumor microenvironment and enhances ovarian cancer immunotherapy. Acta Pharm Sin B. 2024;14(2):854-868.
4. Bao W, Li Z. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer. Crit Rev Oncol Hematol. 2023:104238.
5. Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. Ovarian cancer immunotherapy and personalized medicine. Int J Mol Sci. 2021;22(12):6532.
6. Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G, Jin WL. Immunotherapy for ovarian cancer: adjuvant, combination, and neoadjuvant. Front Immunol. 2020;11:577869.
7. Chen J, Hu J, Gu L, Ji F, Zhang F, Zhang M, et al. Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer. Cancer Immunol Immunother. 2023;72(2):409-425.
8. Fan Z, Han D, Fan X, Zhao L. Ovarian cancer treatment and natural killer cell-based immunotherapy. Front Immunol. 2023;14:13 08143.
9. Xiong J, Wu M, Chen J, Liu Y, Chen Y, Fan G, et al. Cancer-erythrocyte hybrid membrane-camouflaged magnetic nanoparticles with enhanced photothermal-immunotherapy for ovarian cancer. ACS Nano. 2021;15(12):19756-19770.
10. Hu X, Bian C, Zhao X, Yi T. Efficacy evaluation of multi-immunotherapy in ovarian cancer: from bench to bed. Front Immunol. 2022;13:1034903.